Company news

Harrow, Inc. news in 2023

Harrow, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Harrow Completes Transfer of the TRIESENCE® New Drug Application

November 28, 2023

Harrow to Present at Two Investor Conferences in November

November 19, 2023

Harrow Announces Third Quarter 2023 Financial Results

November 12, 2023

Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023

October 29, 2023

Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.

October 23, 2023

Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.

September 28, 2023

Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation

September 25, 2023

Harrow Announces Second Quarter 2023 Financial Results

August 8, 2023

Harrow Launches VIGAMOX® in the U.S.

July 30, 2023

Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023

July 25, 2023

Harrow Prices $60 Million Public Offering of Common Stock

July 18, 2023

Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance

July 17, 2023

Harrow Announces Proposed Public Offering of Common Stock

July 17, 2023

Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq

July 17, 2023

Harrow Acquires Santen’s Branded Ophthalmic Portfolio

July 17, 2023

Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023

May 16, 2023

Harrow Announces First Quarter 2023 Financial Results

May 10, 2023

Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

May 3, 2023

Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S.

May 1, 2023

Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023

April 26, 2023

Harrow Announces New $100 Million Secured Credit Facility with Oaktree

March 27, 2023

Harrow Announces Fourth Quarter and Year-End 2022 Financial Results

March 22, 2023

Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%

March 12, 2023

Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance

March 5, 2023

Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023

March 1, 2023

Harrow Launches Next-Generation Compounded Atropine Formulations

February 14, 2023

Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023

February 1, 2023

Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products

January 22, 2023

Harrow Announces Availability of Fortisite™ Formulations for In-Office Use

January 4, 2023

Calls in 2023

Decks in 2023